The article focuses on the existence of a vaccine and several oral antivirals, chronic hepatitis B virus infection which is the leading cause of liver cancer worldwide. Topics include examines the rate of HBV hospitalizations increased over time with a transient drop around 2007 as coincident with the arrival of new potent oral antivirals, entecavir, and tenofovir.